A Phase 1, Open-Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107, an Agonistic Human Monoclonal Antibody Targeting CD40 in Patients With Advanced Stage Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2018
At a glance
- Drugs ADC 1013 (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 25 Jun 2018 Planned End Date changed from 1 Mar 2020 to 15 Mar 2020.
- 25 Jun 2018 Planned primary completion date changed from 1 Jan 2019 to 7 Jan 2019.
- 28 Feb 2018 Planned End Date changed from 1 Oct 2019 to 1 Mar 2020.